Eli Lilly | LLY - Passivo Circulante





Passivo Circulante Alterar Data
AbbVie USD 42.1B 1.19B 2026-03
Abbott USD 18.38B 1.88B 2026-03
ALKERMES USD 599.5M 56.06M 2026-03
Amgen USD 24.96B 534M 2026-03
AstraZeneca USD 32.57B 1.95B 2026-03
Baxter International USD 3.69B 723M 2026-03
Biogen USD 3B 350.5M 2026-03
Bristol-Myers Squibb USD 19.16B 4.26B 2026-03
Coherus Biosciences USD 140.39M 231.91M 2025-12
Drreddys Laboratories INR 1.76B 62.5M 2025-12
Eli Lilly USD 36.63B 1.41B 2026-03
Gilead Sciences USD 9.48B 2.34B 2026-03
GlaxoSmithKline GBP 22.43B 1.04B 2026-03
Glaxosmithkline GBP 28.82B 144.79M 2025-12
J&J USD 57.72B 3.59B 2026-03
Medtronic USD 9.5B 440M 2025-12
Merck USD 26.94B 1.38B 2026-03
Neurocrine Biosciences USD 831.7M 88.3M 2026-03
Novartis USD 31.37B 4.1B 2026-03
Novartis USD 27.28B 4.72B 2025-12
Novo Nordisk DKK 225.16B 9.5B 2026-03
Perrigo USD 997.6M 15.3M 2026-03
Pfizer USD 34.35B 2.64B 2026-03
Phibro Animal Health USD 281.87M 500K 2026-03
Prestige Brands USD 120.92M 18.63M 2026-03
Regeneron Pharmaceuticals USD 5.11B 739.3M 2026-03
Roche Holding CHF 28B 421M 2025-12
Sanofi EUR 30.01B 1.66B 2026-03
Sanofi EUR 28.35B 9.32B 2025-12
United Therapeutics USD 599.1M 38.5M 2026-03
Zoetis USD 2.05B 182M 2026-03